Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst

Amgen won FDA approval for its highly anticipated migraine drug, Aimovig, last week, and yesterday it racked up its fifth nod for the bone drug Prolia. But investors may be too optimistic that pipelin…
Read the full story: FiercePharma: Pharma